Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships

Bioorg Med Chem Lett. 2012 Oct 15;22(20):6338-42. doi: 10.1016/j.bmcl.2012.08.086. Epub 2012 Aug 30.

Abstract

Starting with Nutlins as an initial lead, we designed and generated bicyclic scaffolds aiming to place cis-bischlorophenyl moiety at the equivalent location where the hydrophobic interaction with MDM2 could be expected. As a result, we discovered novel MDM2 inhibitors possessing a dihydroimidazothiazole scaffold. Further exploration of the side chains on the dihydroimidazothiazole scaffold aided by molecular modeling resulted in compounds exhibiting almost comparable in vitro potency to Nutlin-3a.

MeSH terms

  • Drug Design*
  • Humans
  • Imidazoles / chemistry
  • Imidazoles / pharmacology
  • Neoplasms / drug therapy
  • Protein Interaction Maps / drug effects*
  • Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-mdm2 / metabolism
  • Thiazoles / chemistry*
  • Thiazoles / pharmacology*
  • Tumor Suppressor Protein p53 / antagonists & inhibitors*
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Imidazoles
  • Thiazoles
  • Tumor Suppressor Protein p53
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2